...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method
【24h】

Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method

机译:基于结合构象和配体的方法发现基于共晶结构的新型IKKβ抑制剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

IκB kinase β (IKKβ), an attractive anti-inflammation and anti-cancer target, plays a crucial role in the activation of NF-κB signalling pathway. To identify novel IKKβ inhibitors, we combined structure-based and ligand-based methods based on the co-crystal structure of IKKβ. According to the chemical similarity, 162 reported IKKβ inhibitors were divided into five classes. For each class, a 3D pharmacophore model was established based on the binding conformations of the compounds. The validated models were further used in virtual screening. Twelve drugable compounds were retained for biological test, resulting in two novel inhibitors with IC50 values lower than 10 μM. Compared to other models, our method considers the crystal structure of IKKβ for the first time.
机译:IκB激酶β(IKKβ)是有吸引力的抗炎和抗癌靶标,在NF-κB信号通路的激活中起着至关重要的作用。为了鉴定新型的IKKβ抑制剂,我们基于IKKβ的共晶体结构,结合了基于结构和基于配体的方法。根据化学相似性,已报道的162种IKKβ抑制剂分为五类。对于每一类,基于化合物的结合构象建立3D药效团模型。验证的模型进一步用于虚拟筛选。保留了十二种可药用化合物进行生物学测试,从而产生了两种新型抑制剂,IC50值均低于10μM。与其他模型相比,我们的方法首次考虑了IKKβ的晶体结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号